Clinical trial
Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and…
NCT00479128 · M.D. Anderson Cancer Center, Other · Active, not recruiting
Key facts
| NCT number | NCT00479128 |
|---|---|
| Title | Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors |
| Official title | Phase I Two-Dimensional Dose-Finding Study of Bortezomib in Combination With Gemcitabine/Doxorubicin in Metastatic Surgically Unresectable Urothelial Cancer or Other Solid Tumors |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Status | Active, not recruiting |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Solid Tumor, Urethral Cancer |
| Intervention type | Drug |
| Interventions | Bortezomib, Gemcitabine, Doxorubicin |
| Enrollment | 80 |
| Start date | Sep 28, 2006 |
| Primary completion | Sep 30, 2026 |
| Completion | Sep 30, 2026 |
| First posted | May 25, 2007 |
| Last update posted | Oct 28, 2025 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: